SPY757.55+0.06%QQQ688.42+0.04%BTC/USD71,424.86−3.39%DIA522.45−0.00%GLD355.43+0.15%TLT79.70−0.03%

Myriad Genetics Inc

MYGNNASDAQ

Trade with Public

$5.68

-0.04-0.7%

Last update: Nov 12, 4:05 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Myriad Genetics (MYGN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Myriad Genetics (MYGN) stock.

Analyst Consensus — 12 Analysts

6Buy

3Hold

3Sell

# Analysts12

Latest Upgrades and Downgrades for Myriad Genetics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Stephens & Co.	Mason Carrico	PT Raise	Equal-Weight	$3→$6
—	TD Cowen	Kyle Boucher	PT Raise	Hold	$5→$7
—	Leerink Partners	Puneet Souda	PT Raise	Market Perform	$5→$8
—	TD Cowen	Kyle Boucher	PT Raise	Hold	$4→$5
—	Craig-Hallum	John Wilkin	PT Raise	Buy	$4→$8
—	UBS	Lu Li	PT Cut	Neutral	$6→$4
—	Piper Sandler	David Westenberg	Downgrade	Overweight→Underweight	$5→$2
—	Stephens & Co.	Mason Carrico	PT Cut	Equal-Weight	$5→$3
—	Wells Fargo	Evan Stampler	PT Cut	Equal-Weight	$6→$3
—	TD Cowen	Kyle Boucher	PT Cut	Hold	$6→$4
—	TD Cowen	Kyle Boucher	PT Cut	Hold	$7→$6
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$6→$6
—	UBS	Lu Li	PT Cut	Neutral	$8→$6
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$7→$6
—	Piper Sandler	Dave Weiner	PT Cut	Overweight	$9→$9
—	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$6→$7
—	TD Cowen	Dan Brennan	PT Raise	Hold	$8→$9
—	UBS	Lu Li	PT Raise	Neutral	$6→$8
—	Scotiabank	Sung Ji Nam	Downgrade	Sector Outperform→Sector Perform	$20→$6
—	Piper Sandler	Dave Weiner	PT Cut	Overweight	$13→$9

Myriad Genetics Inc

Myriad Genetics (MYGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Myriad Genetics Stock

Myriad Genetics (MYGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Myriad Genetics Stock

Analyst Ratings News

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PRO
Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PRO
Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

Myriad Genetics Inc

Myriad Genetics (MYGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Myriad Genetics Stock

Myriad Genetics (MYGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Myriad Genetics Stock

Analyst Ratings News

PROStephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PROTD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PROLeerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PROTD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PROCraig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PROUBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

People Also Watch

People Also Watch

Analyst Ratings News

PROStephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PROTD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PROLeerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PROTD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PROCraig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PROUBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PRO
Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

PRO
Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

PRO
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6